DaVita (NYSE:DVA) Issues Earnings Results

Key Points

• DaVita Inc. reported earnings of $2.95 per share, exceeding analysts' expectations by $0.25, showcasing a strong performance against a consensus estimate of $2.70.
• The company experienced a significant increase in stock value, with shares trading up $1.46 to reach $140.98, although the stock has fluctuated within a range between $131.76 and $179.60 over the past year.
• Analysts have mixed views on DaVita's stock, with ratings ranging from sell to buy, and a consensus rating of "Hold" with an average price target of $167.40.

DaVita (NYSE:DVA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.70 by $0.25, Zacks reports. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 246.39%. The company's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.00 EPS. DaVita updated its FY 2025 guidance to 10.200-11.300 EPS.

DaVita Stock Down 0.8%

Shares of DVA stock traded down $1.06 during midday trading on Thursday, reaching $126.76. 466,939 shares of the stock were exchanged, compared to its average volume of 867,785. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. DaVita has a 1 year low of $126.07 and a 1 year high of $179.60. The firm has a market cap of $9.57 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09. The company's 50 day moving average is $140.32 and its two-hundred day moving average is $147.34.

Insider Buying and Selling

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares of the company's stock, valued at $3,905,700. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.00% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DaVita stock. NewEdge Advisors LLC boosted its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 20.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 511 shares of the company's stock after purchasing an additional 88 shares during the quarter. NewEdge Advisors LLC's holdings in DaVita were worth $78,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on DVA shares. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Barclays dropped their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research report on Thursday. Finally, Truist Financial lowered their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research note on Monday, May 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $165.60.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.